Dendreon Revenue Growth Rates (DNDN), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Dendreon Corp  (DNDN)
 

DNDN's Revenue Growth by Quarter and Year

Dendreon's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

DNDN Revenue (in millions $) FY 2014 FY 2013 FY 2012 FY 2011
4th Quarter December -
3rd Quarter September 73.12
2nd Quarter June 82.21
1st Quarter March 68.78
FY 224.11





DNDN Revenue third quarter 2014 Y/Y Growth Comment
Dendreon Corp reported Revenue growth of 7.53% year on year in the third quarter 2014, to $ 73.12 millions, this is lower than Dendreon Corp's recent average Revenue surge of 13131.53%.

Looking into third quarter 2014 results within Biotechnology & Pharmaceuticals industry 34 other companies have achieved higher Revenue growth. While Dendreon Corp' s Revenue increase of 7.53% ranks overall at the positon no. 1975 in the third quarter 2014.


DNDN Revenue ( Y/Y Growth %) 2014
 2013 2012 2011
4th Quarter December - -12.46 % -57.71 % 708.28 %
3rd Quarter September 7.53 % -12.79 % 21.28 % 217.95 %
2nd Quarter June 12.12 % -8.34 % 66.09 % 1613.88 %
1st Quarter March 1.76 % -17.64 % 203.74 % 135000 %
FY   - -12.83 % -4.71 % -

Financial Statements
Dendreon's third quarter 2014 Revenue $ 73.12 millions DNDN's Income Statement
Dendreon's third quarter 2013 Revenue $ 68.00 millions Quarterly DNDN's Income Statement


DNDN Revenue (Quarter on Quarter Growth %)

 2014
 2013 2012 2011
4th Quarter December - 10.06 % 9.64 % 214.43 %
3rd Quarter September -11.05 % -7.26 % -2.53 % 33.49 %
2nd Quarter June 19.53 % 8.48 % -2.53 % 78.24 %
1st Quarter March -8.1 % -20.94 % -59.4 % 8.04 %
FY (Year on Year)   - -12.83 % -4.71 % -


Back to DNDN Growth rate Comparisons >> Back to DNDN Growth rate Comparisons >>


Revenue third quarter 2014 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #35
Healthcare Sector #271
Overall #1975

Revenue Y/Y Growth Statistics
High Average Low
128576.19 % 13131.53 % -57.71 %
(Jun 30 2014)   (Mar 31 2013)
Revenue third quarter 2014 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #35
Healthcare Sector #271
Overall #1975
Revenue Y/Y Growth Statistics
High Average Low
128576.19 % 13131.53 % -57.71 %
(Jun 30 2014)   (Mar 31 2013)

Revenue by Quarter for the Fiscal Years 2011, 2012, 2013, 2014

Dendreon's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
13280.95 % 747.07 % -59.4 %
(Jun 30 2010)  


DNDN's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2014 Dendreon Corp disclosed drop in Revenue from the second quarter by -11.05% to $ 73.12 millions, from $ 82.21 millions achived in the previous reporting period.

But that's not important problem, as Dendreon's Revenue generally seem to plunge in this quarter.

Within Biotechnology & Pharmaceuticals industry 43 other companies have achieved higher Revenue quarter on quarter growth. While Dendreon's Revenue growth quarter on quarter, overall rank is 3632.


Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #44
Healthcare Sector #417
Overall #3632
Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #44
Healthcare Sector #417
Overall #3632
Revenue Q/Q Growth Statistics
High Average Low
13280.95 % 747.07 % -59.4 %
(Jun 30 2010)  


DNDN's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2014 Dendreon Corp disclosed drop in Revenue from the second quarter by -11.05% to $ 73.12 millions, from $ 82.21 millions achived in the previous reporting period.

But that's not important problem, as Dendreon's Revenue generally seem to plunge in this quarter.

Within Biotechnology & Pharmaceuticals industry 43 other companies have achieved higher Revenue quarter on quarter growth. While Dendreon's Revenue growth quarter on quarter, overall rank is 3632.


Dendreon's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2014)		 12 Months Ending
(Jun 30 2014)		 12 Months Ending
(Mar 31 2014)		 12 Months Ending
(Dec 31 2013)		 12 Months Ending
(Sep 30 2013)
Cumulative Revenue 12 Months Ending $ 298.95 $ 293.83 $ 284.93 $ 283.75 $ 294.40
Y / Y Revenue Growth (TTM) 1.54 % -3.46 % -8.4 % -12.84 % -33.42 %
Year on Year Revenue Growth Overall Ranking # 2571 # 2330 # 2330 # 0 # 0
Seqeuential Revenue Change (TTM) 1.74 % 3.12 % 0.42 % -3.62 % -3.28 %
Seq. Revenue Growth (TTM) Overall Ranking # 2386 # 1793 # 0 # 0 # 2341


Cumulative Revenue growth Comment
With 1.54% annual Revenue growth, Dendreon Corp would report a record annual Revenue improvement if the fiscal year would end on Sep 30 2014.

In the Healthcare sector 268 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 2330 to 2571.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 26
Healthcare Sector # 269
Overall # 2571

Revenue TTM Y/Y Growth Statistics
High Average Low
1.54 %
 -5.79 %
-12.84 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 26
Sector # 236
S&P 500 # 2386
Cumulative Revenue growth Comment
With 1.54% annual Revenue growth, Dendreon Corp would report a record annual Revenue improvement if the fiscal year would end on Sep 30 2014.

In the Healthcare sector 268 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 2330 to 2571.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 26
Healthcare Sector # 269
Overall # 2571

Revenue TTM Y/Y Growth Statistics
High Average Low
1.54 %
-5.79 %
-12.84 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 26
Sector # 236
S&P 500 # 2386




Other Revenue Growth
Biotechnology & Pharmaceuticals Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
DNDN's Revenue Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue improvement for the quarter ending Sep 30 2014 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2014
Spectrum Pharmaceuticals Inc 13.08%$ 13.080 millions
Pediatrix Medical Group Inc 12.94%$ 12.939 millions
Orasure Technologies Inc12.87%$ 12.865 millions
Positron Corporation12.82%$ 12.821 millions
Celldex Therapeutics inc 12.35%$ 12.347 millions
Nuvasive Inc12.27%$ 12.274 millions
Charles River Laboratories International inc 12.13%$ 12.131 millions
Sonida Senior Living Inc 11.93%$ 11.934 millions
Star Equity Holdings Inc 11.83%$ 11.826 millions
Merit Medical Systems Inc11.80%$ 11.803 millions
Henry Schein Inc 11.70%$ 11.698 millions
Endologix Inc11.70%$ 11.696 millions
Luminex Corporation11.63%$ 11.627 millions
National Healthcare Corp11.47%$ 11.468 millions
Tivity Health Inc 11.43%$ 11.428 millions
Remedent Inc 11.34%$ 11.339 millions
Cutera Inc 11.28%$ 11.279 millions
Baxter International Inc 11.21%$ 11.208 millions
Universal Health Services Inc 11.09%$ 11.087 millions
Lisata Therapeutics Inc 11.08%$ 11.084 millions
Stryker Corp11.06%$ 11.065 millions
Tvardi Therapeutics Inc 10.51%$ 10.511 millions
Teleflex Incorporated10.48%$ 10.483 millions
Intuitive Surgical Inc 10.24%$ 10.240 millions
Lifeloc Technologies Inc 10.11%$ 10.112 millions
Orthofix Medical Inc 10.01%$ 10.008 millions
Globus Medical Inc 9.89%$ 9.889 millions
Zoetis Inc 9.70%$ 9.701 millions
Masimo Corp9.64%$ 9.640 millions
Hill rom Holdings Inc 9.57%$ 9.568 millions


About Dendreon Revenue Growth Rates (DNDN), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: the company’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.